title: Assessment of interleukin-6 receptor inhibition therapy on periodontal condition in patients with rheumatoid arthritis and chronic periodontitis.
abstract: BACKGROUND
  Overproduction of interleukin (IL)-6 may play a pathologic role in rheumatoid arthritis (RA) and chronic periodontitis (CP). The present study assesses IL-6 receptor (IL-6R) inhibition therapy on the periodontal condition of patients with RA and CP.
  
  
  METHODS
  The study participants were 28 patients with RA and CP during treatment with IL-6R inhibitor, and 27 patients with RA and CP during treatment without IL-6R inhibitor. Periodontal and rheumatologic parameters and serum levels of cytokine and inflammatory markers and immunoglobulin G against periodontopathic bacteria were examined after medication with IL-6R inhibitor for 20.3 months on average (T1) and again 8 weeks later (T2).
  
  
  RESULTS
  No differences were observed between the groups in any parameter values at T1, except for serum IL-6 levels. The anti-IL-6R group showed a significantly greater decrease in gingival index, bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL), and serum levels of IL-6 and matrix metalloproteinase (MMP)-3 from T1 to T2 than the control group (P <0.05). A significant correlation was found between changes in serum anticyclic citrullinated peptide levels and those in PD and CAL in the anti-IL-6R group (P <0.05), whereas both groups exhibited a significant association between changes in serum MMP-3 levels and those in BOP (P <0.05).
  
  
  CONCLUSIONS
  Changes in periodontal and serum parameter values were different between the patients with RA and CP during treatment with and without IL-6R inhibitor.
authors.affiliation: Division of Periodontology, Department of Oral Biological Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Moe
authors.initials: M
authors.lastname: Okada
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ito
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kobayashi
authors.forename: Kohei
authors.initials: K
authors.lastname: Ishida
authors.forename: Anri
authors.initials: A
authors.lastname: Kojima
authors.forename: Ichiei
authors.initials: I
authors.lastname: Narita
authors.forename: Akira
authors.initials: A
authors.lastname: Murasawa
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Yoshie
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016976:Aggregatibacter actinomycetemcomitans / Q000276:immunology; D000907:Antibodies, Bacterial / Q000097:blood; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000032:analysis; D055113:Chronic Periodontitis / Q000188:drug therapy* / Q000382:microbiology; D003774:Dental Plaque Index; D016124:Eikenella corrodens / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D018836:Inflammation Mediators / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D017622:Periodontal Attachment Loss / Q000188:drug therapy; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000188:drug therapy; D016966:Porphyromonas gingivalis / Q000276:immunology; D018713:Prevotella intermedia / Q000276:immunology; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000907:Antibodies, Bacterial; D061067:Antibodies, Monoclonal, Humanized; C508600:IL6 protein, human; D007074:Immunoglobulin G; D018836:Inflammation Mediators; D015850:Interleukin-6; D010446:Peptide Fragments; D019947:Receptors, Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; C511768:MMP3 protein, human; D019278:Matrix Metalloproteinase 3; C502936:tocilizumab